Communiqués

11/08 Cipher Pharmaceuticals Reports Second Quarter 2026 Results AQ
31/07 Cipher Pharmaceuticals Schedules Q2 2026 Earnings Release and Conference Call AQ
06/07 Cipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris® AQ
18/06 Cipher Pharmaceuticals Announces Results of Annual General Meeting of Shareholders AQ
08/05 Cipher Pharmaceuticals : Quarterly Report Q1 2026 PU
07/05 Cipher Pharmaceuticals Reports First Quarter Results AQ
01/05 Cipher Pharmaceuticals Announces Normal Course Issuer Bid AQ
29/04 Cipher Pharmaceuticals Schedules Q1 2026 Earnings Release and Conference Call AQ
08/04 Cipher Pharmaceuticals : AIF 2025 PU
12/03 Cipher Pharmaceuticals : Annual Report 2025 PU
12/03 Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings AQ
04/03 Cipher Pharmaceuticals Schedules Q4 & Fiscal 2025 Earnings Release and Conference Call AQ
28/01 Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™ (Spinosad) AQ
06/11 Cipher Pharmaceuticals : Quarterly Report Q3 2025 PU
06/11 Cipher Pharmaceuticals Reports Third Quarter 2025 Results AQ
29/10/25 Cipher Pharmaceuticals Schedules Q3 2025 Earnings Release and Conference Call AQ
14/10/25 Cipher Pharmaceuticals Receives Successful Arbitration Award AQ
26/08/25 Cipher Pharmaceuticals Announces the Passing of Director Mr. Harold Wolkin AQ
08/08/25 Cipher Pharmaceuticals : Quarterly Report Q2 2025 PU
07/08/25 Cipher Pharmaceuticals Reports Second Quarter 2025 Results, Including Record Revenue AQ
29/07/25 Cipher Pharmaceuticals Schedules Q2 2025 Earnings Release and Conference Call AQ
13/06/25 Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders AQ
08/05/25 Cipher Pharmaceuticals Reports First Quarter 2025 Results, and Announces $15 Million Debt Repayment AQ
02/05/25 Cipher Pharmaceuticals Schedules Q1 2025 Earnings Release and Conference Call AQ
01/05/25 Cipher Pharmaceuticals Announces Normal Course Issuer Bid, Including Intention to Utilize Block Purchases AQ
Aucun résultat pour cette recherche